Beneficial Effect Of Crotamine In The Treatment Of Myasthenic Rats

Introduction: Crotamine is a basic, low-molecular-weight peptide that, at low concentrations, improves neurotransmission in isolated neuromuscular preparations by modulating sodium channels. In this study, we compared the effects of crotamine and neostigmine on neuromuscular transmission in myasthenic rats. Methods: We used a conventional electromyographic technique in in-situ neuromuscular preparations and a 4-week treadmill program. Results: During the in-situ electromyographic recording, neostigmine (17 μg/kg) caused short-term facilitation, whereas crotamine induced progressive and sustained twitch-tension enhancement during 140 min of recording (50 ± 5%, P < 0.05). On the treadmill evaluation, rats showed significant improvement in exercise tolerance, characterized by a decrease in the number of fatigue episodes after 2 weeks of a single-dose treatment with crotamine. Conclusions: These results indicate that crotamine is more efficient than neostigmine for enhancing muscular performance in myasthenic rats, possibly by improving the safety factor of neuromuscular transmission. © 2012 Wiley Periodicals, Inc.474591593Dierdorf, S.F., Walton, S., Anesthesia for patients with rare and coexisting diseases (2006) Clinic anesthesia, p. 502. , Barash PG, Cullen BF, Soelting RK, editors., 5th ed. Philadelphia: Lippincott Williams and WilkinsArgov, Z., Management of myasthenic conditions: nonimmune issues (2009) Curr Opin Neurol, 22, pp. 493-497Qian-Sheng, Y., Harold, W.H., Weiming, L., Debomoy, K.L., Arnold, B., Nigel, H., Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine (2010) Bioorg Med Chem, 18, pp. 4687-4693Barrio, A., Vital Brazil, O., Neuromuscular action of the Crotalus terrificus terrificus poisons (1951) Acta Physiol Latinoam, 1, pp. 291-308Gonçalves, J.M., Polson, A., The electrophoretic analysis of snake venoms (1947) Arch Biochem, 13, pp. 253-259Gonçalves, J.M., Estudos sobre venenos de serpentes brasileiras. II-Crotalus terrificus crotaminicus, subespécie biológica (1956) Ann Acad Bras Ci{ring in equal to}nc, 28, pp. 365-367Rádis-Baptista, G., Kerkis, I., Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties (2011) Curr Pharm Des, 17, pp. 4351-4361Ownby, C.L., Structure, function and biophysical aspects of the myotoxins from snake venoms (1998) J Toxicol Toxin Rev, 17, pp. 213-238Vital Brazil, O., Prado-Franceschi, J., Laure, C.J., Repetitive muscle responses induced by crotamine (1979) Toxicon, 17, pp. 61-69Matavel, A.C.S., Ferreira-Alves, D.L., Beirão, P.S.L., Cruz, J.S., Tension generation and increase of voltage-activated sodium current by crotamine (1998) Eur J Pharmacol, 348, pp. 167-173Vital Brazil, O., Fontana, M.D., Toxins as tools in the study of sodium channel distribution in the muscle fiber membrane (1993) Toxicon, 31, pp. 1085-1098Chang, C.C., Tseng, K.H., Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle (1978) Br J Pharmacol, 63, pp. 551-559Camillo, M.A.P., Arruda Paes, P.C., Troncone, L.R.P., Rogero, J.R., Gyroxin fails to modify in vitro release of labeled dopamine and acetylcholine from rat and mouse striatal tissue (2001) Toxicon, 39, pp. 843-853Kawanami, S., Mori, S., Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein (1994) Fukuoka Igaku Zasshi, 85, pp. 120-127Dal Belo, C.A., Leite, G.B., Fontana, M.D., Corrado, A.P., Zanandréa Baso, A.C., New evidence for a presynaptic action of prednisolone at neuromuscular junction (2002) Muscle Nerve, 26, pp. 37-43Brown, G.L., The neuromuscular junction (1938) J Physiol, 92, p. 22Priviero, F., De Nucci, G., Antunes, E., Zanesco, A., Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training (2004) Clin Exp Pharmacol Physiol, 31, pp. 741-743Pourmand, R., Myasthenia gravis (1997) Dis Mon, 43, pp. 65-109Tzartos, S.J., Barkas, T., Cung, M.T., Mamalaki, A., Marraud, M., Orlewski, F., Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor (1998) Immunol Rev, 163, pp. 89-120Serra, A., Ruff, R., Kaminski, H., Leigh, J.R., Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles (2011) Ann NY Acad Sci, 1233, pp. 26-33Pritchard, E.A.B., The use of "Prostigmin" in the treatment of myasthenia gravis (1935) Lancet, 1, pp. 432-434Sieb, J.P., Myasthenia gravis: emerging new therapy options (2005) Curr Opin Pharmacol, 5, pp. 303-307Mehndiratta, M.M., Pandey, S., Kuntzer, T., Acetylcholinesterase inhibitor treatment for myasthenia gravis (2011) Cochrane Database Syst Rev, 16, pp. CD006986Mantegazza, R., Bonanno, S., Camera, G., Antozzi, C., Current and emerging therapies for the treatment of myasthenia gravis (2011) Neuropsychiatr Dis Treat, 7, pp. 151-160Richman, D.P., Agius, M.A., Treatment of autoimmune myasthenia gravis (2003) Neurology, 61, pp. 1652-1661Toyama, M.H., Marangoni, S., Novello, J.C., Leite, G.B., Prado-Franceschi, J., da Cruz-Höfling, M.A., Biophysical, histopathological and pharmacological characterization of crotamine isoforms F22 and F32 (2003) Toxicon, 41, pp. 493-500Ponce-Soto, L.A., Martins-de-Souza, D., Novello, J.C., Marangoni, S., Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom (2007) Protein J, 26, pp. 533-540Ponce-Soto, L.A., Martins-de-Souza, D., Marangoni, S., Structural and pharmacological characterization of the crotamine isoforms III-4 (MYX4-CROCu) and III-7 (MYX7-CROCu) isolated from the Crotalus durissus cumanensis venom (2010) Toxicon, 55, pp. 1443-1452Slater, C.R., Structural factors influencing the efficacy of neuromuscular transmission (2008) Ann NY Acad Sci, 1132, pp. 1-1